Posters

Goniotomy via trabecular meshwork excision performed with Kahook Dual Blade combined with phacoemulsification and goniosynechialysis for angle-closure glaucoma: 12 month results

Poster Details

First Author: S.Dorairaj USA

Co Author(s):                        

Abstract Details

Purpose:

To characterize reductions in intraocular pressure (IOP) and the need for IOP-lowering medications following phacoemulsification combined with goniosynechialysis and goniotomy via the trabecular meshwork (TM) performed with the Kahook Dual Blade in eyes with angle-closure glaucoma and cataract.

Setting:

Mayo Clinic, Jacksonville, FL

Methods:

This was a retrospective, interventional case series in 22 patients. The key inclusion criteria were: patients 18-90 years of age; diagnosed with angle-closure glaucoma and visually significant cataract; undergoing combined phacoemulsification with intraocular lens (IOL) implantation, goniosynechialysis, and goniotomy via TM excision using the Kahook Dual Blade. Preoperative, operative, and postoperative data were collected through 12 months of follow-up. Outcomes included mean IOP reduction, reduction in IOP-lowering medications, and the proportion of patients achieving IOP reductions >20%, IOP <18 mmHg, and a reduction of >1 IOP-lowering medications.

Results:

Mean IOP was significantly reduced from 24.7 mmHg at baseline to 19.3 mmHg at Day 1, 16.0 mmHg at Week 1, 12.2 mmHg at 1 month, 12.1 mmHg at 6 months, and 12.5 mm Hg at 12 months (P<0.05). The mean number of IOP-lowering medications significantly decreased after surgery from 2.3 at baseline to 0.1 at Month 1 and Month 6, and 0.2 at Month 12 (P<0.05). Mean LogMAR scores significantly improved after surgery from 0.51 at baseline to 0.04 at Month 12 (P<0.05).

Conclusions:

Phacoemulsification combined with goniosynechialysis and goniotomy, via TM excision performed with the Kahook Dual Blade, safely provides statistically and clinically meaningful reductions in both IOP and the need for IOP-lowering medications in eyes with angle-closure glaucoma.

Financial Disclosure:

travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented